(−)‐o‐[11C]methyl‐trans‐decalinvesamicol ((−)‐[11C]OMDV) as a PET ligand for the vesicular acetylcholine transporter
Abstract
To develop a PET imaging agent to visualize brain cholinergic neurons and synaptic changes caused by Alzheimer's disease, (−)‐ and (+)‐o‐[11C]methyl‐trans‐decalinvesamicol ([11C]OMDV) were isolated and investigated for differences in not only their binding affinity and selectivity to vesicular acetylcholine transporter (VAChT), but also their in vivo activities. [11C]OMDV has a high binding affinity for VAChT both in vitro and in vivo. Racemic OMDV and o‐trimethylstannyl‐trans‐decalinvesamicol (OTDV), which are precursors for synthesis of [11C]OMDV, were separated into (−)‐optical isomers ((−)‐OMDV and (−)‐OTDV) and (+)‐optical isomers ((+)‐OMDV and (+)‐OTDV) by HPLC. In the in vitro binding assay, (−)‐OMDV(7.2 nM) showed eight times higher binding affinity (Ki) to VAChT than that of (+)‐OMDV(57.5 nM). In the biodistribution study, the blood–brain barrier permeability of both enantiomers ((−)‐[11C]OMDV and (+)‐[11C]OMDV) was similarly high (about 1.0%ID/g) at 2 min post‐injection. However, (+)‐[11C]OMDV clearance from the brain was faster than (−)‐[11C]OMDV. In the in vivo blocking study, accumulation of (−)‐[11C]OMDV in the cortex was markedly decreased (approximately 30% of control) by coadministration of vesamicol, and brain uptake of (−)‐[11C]OMDV was not significantly altered by coadministration of (+)‐pentazocine or (+)‐3‐(3‐hydroxyphenyl)‐N‐propylpiperidine ((+)‐3‐PPP). PET‐CT imaging revealed inhibition of the rat brain uptake of (−)‐[11C]OMDV by coadministration of vesamicol. In conclusion, (−)‐[11C]OMDV, which is an enantiomer of OMDV, selectively binds to VAChT with high affinity in the rat brain in vivo. (−)‐[11C]OMDV may be utilized as a potential PET ligand for studying presynaptic cholinergic neurons in the brain.Keywords
This publication has 34 references indexed in Scilit:
- Synthesis and in Vitro and in Vivo Evaluation of18F-Labeled Positron Emission Tomography (PET) Ligands for Imaging the Vesicular Acetylcholine TransporterJournal of Medicinal Chemistry, 2009
- The potential of (−)‐o‐[11C]methylvesamicol for diagnosing cholinergic deficit dementiaSynapse, 2008
- A new 18F-labeled fluoroacetylmorpholino derivative of vesamicol for neuroimaging of the vesicular acetylcholine transporterNuclear Medicine and Biology, 2007
- Mice Deficient for the Vesicular Acetylcholine Transporter Are Myasthenic and Have Deficits in Object and Social RecognitionNeuron, 2006
- Synthesis and biological characterization of stable and radioiodinated (±)-trans-2-hydroxy-3-P{4-(3-iodophenyl)piperidyl}-1,2,3,4-tetrahydronaphthalene (3′-IBVM)Nuclear Medicine and Biology, 2000
- On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic HypothesisExperimental Neurology, 2000
- Synthesis and preliminary evaluation of [123I]1-(4-cyanobenzyl)-4-[[(trans-iodopropen-2-yl)oxy]-methyl]piperidine: A novel high affinity sigma receptor radioligand for SPECTNuclear Medicine and Biology, 1997
- A radiotracer for mapping cholinergic neurons of the brainJournal of Medicinal Chemistry, 1990
- The vesicular acetylcholine transport systemTrends in Neurosciences, 1987
- The 12th J. A. F. Stevenson Memorial Lecture: Aging, Alzheimer's disease, and the cholinergic systemCanadian Journal of Physiology and Pharmacology, 1984